Finding the right combination for neoadjuvant therapy in high-risk, stage III melanoma

Am J Manag Care. 2019 Feb;25(2 Spec No.):SP43-SP44.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Combined Modality Therapy
  • Humans
  • Immunotherapy / methods*
  • Melanoma / drug therapy
  • Melanoma / pathology
  • Melanoma / surgery
  • Melanoma / therapy*
  • Melanoma, Cutaneous Malignant
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Prognosis
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology
  • Skin Neoplasms / surgery
  • Skin Neoplasms / therapy*

Substances

  • Antineoplastic Agents